...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: ZEN-3694 Single Agent Trial Status
6
Oct 24, 2017 11:18AM
1
Oct 25, 2017 09:02AM
2
Oct 26, 2017 10:24AM
5
Oct 26, 2017 12:13PM

Nov 02, 2017 03:38PM

Nov 02, 2017 04:29PM

Nov 03, 2017 10:49AM

Nov 03, 2017 10:58AM

Nov 03, 2017 12:07PM
2
Nov 03, 2017 03:45PM
2
Nov 03, 2017 04:23PM
5
Nov 18, 2017 07:45PM

narmac - Liquidity is definitely an issue however not impossible if the shares are in a cash account or non registered account. I have heard of a number transactions that have occurred with Zenith shares between .10 and .65. There is some liquidity just not much. In these cases that I have heard about it was the buyer that had the upper hand. This lack of liquidity may also force some that would otherwise deal their future away into hanging onto to those shares and collect a future royalty despite themselves. Wouldn't that be a nice gift if it actually happens. My fingers are crossed. We should have a better idea what to expect before the end of this year and frankly it wouldn't surprise me to get a good indication within the next 6 months. The lack of control of ones own destiny is frustrating without question.

tada

Share
New Message
Please login to post a reply